• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Global Cord Blood Corporation

    2/3/23 8:00:39 AM ET
    $CO
    Managed Health Care
    Health Care
    Get the next $CO alert in real time by email
    SC 13G 1 eh230326844_13g-co.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.   )*

     

    Global Cord Blood Corporation

    (Name of Issuer)
     

    Ordinary shares, par value US$0.0001 per share

    (Title of Class of Securities)
     

    G39342103

    (CUSIP Number)
     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☐ Rule 13d-1(c)
      ☒ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

       

     

     

    CUSIP No. G39342103 SCHEDULE 13G Page 2 of 11

     

     

    1

    NAME OF REPORTING PERSON

     

    PAGAC III Holding VII Limited

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    British Virgin Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    9,500,000(1)

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    9,500,000(1)

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    9,500,000(1)

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.8%(2)

     
    12

    TYPE OF REPORTING PERSON

     

    CO

     

     

     

    (1) Represents 9,500,000 Ordinary Shares (as defined below) held by PAGAC III Holding VII Limited. See Item 4 of the statement for additional information.

    (2) This percentage is calculated based on 121,551,075 Ordinary Shares outstanding as of March 31, 2022 pursuant to the Issuer’s Form 20-F filed with the United States Securities and Exchange Commission (the “SEC”) on August 16, 2022.

     

       

     

     

    CUSIP No. G39342103 SCHEDULE 13G Page 3 of 11

     

     

    1

    NAME OF REPORTING PERSON

     

    PAG Asia I LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    9,500,000(1)

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    9,500,000(1)

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    9,500,000(1)

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.8%(2)

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

     

    (1) Represents 9,500,000 Ordinary Shares held by PAGAC III Holding VII Limited. See Item 4 of the statement for additional information.

    (2) This percentage is calculated based on 121,551,075 Ordinary Shares outstanding as of March 31, 2022 pursuant to the Issuer’s Form 20-F filed with the SEC on August 16, 2022.

     

       

     

     

    CUSIP No. G39342103 SCHEDULE 13G Page 4 of 11

     

     

    1

    NAME OF REPORTING PERSON

     

    PAG Asia Capital GP I Limited

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    9,500,000(1)

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    9,500,000(1)

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    9,500,000(1)

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.8%(2)

     
    12

    TYPE OF REPORTING PERSON

     

    CO

     

     

     

    (1) Represents 9,500,000 Ordinary Shares held by PAGAC III Holding VII Limited. See Item 4 of the statement for additional information.

    (2) This percentage is calculated based on 121,551,075 Ordinary Shares outstanding as of March 31, 2022 pursuant to the Issuer’s Form 20-F filed with the SEC on August 16, 2022.

     

       

     

     

    CUSIP No. G39342103 SCHEDULE 13G Page 5 of 11

     

     

    1

    NAME OF REPORTING PERSON

     

    PAG Capital Limited

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    9,500,000(1)

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    9,500,000(1)

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    9,500,000(1)

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.8%(2)

     
    12

    TYPE OF REPORTING PERSON

     

    CO

     

     

     

    (1) Represents 9,500,000 Ordinary Shares held by PAGAC III Holding VII Limited. See Item 4 of the statement for additional information.

    (2) This percentage is calculated based on 121,551,075 Ordinary Shares outstanding as of March 31, 2022 pursuant to the Issuer’s Form 20-F filed with the SEC on August 16, 2022.

     

       

     

     

    CUSIP No. G39342103 SCHEDULE 13G Page 6 of 11

     

     

    1

    NAME OF REPORTING PERSON

     

    Pacific Alliance Group Limited

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    9,500,000(1)

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    9,500,000(1)

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    9,500,000(1)

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.8%(2)

     
    12

    TYPE OF REPORTING PERSON

     

    CO

     

     

     

    (1) Represents 9,500,000 Ordinary Shares held by PAGAC III Holding VII Limited. See Item 4 of the statement for additional information.

    (2) This percentage is calculated based on 121,551,075 Ordinary Shares outstanding as of March 31, 2022 pursuant to the Issuer’s Form 20-F filed with the SEC on August 16, 2022.

     

       

     

     

    CUSIP No. G39342103 SCHEDULE 13G Page 7 of 11

     

     

    1

    NAME OF REPORTING PERSON

     

    PAG

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    9,500,000(1)

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    9,500,000(1)

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    9,500,000(1)

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.8%(2)

     
    12

    TYPE OF REPORTING PERSON

     

    CO

     

     

     

    (1) Represents 9,500,000 Ordinary Shares held by PAGAC III Holding VII Limited. See Item 4 of the statement for additional information.

    (2) This percentage is calculated based on 121,551,075 Ordinary Shares outstanding as of March 31, 2022 pursuant to the Issuer’s Form 20-F filed with the SEC on August 16, 2022.

     

       

     

     

    CUSIP No. G39342103 SCHEDULE 13G Page 8 of 11

     

     

    Item 1. (a) Name of Issuer
         
     

    Global Cord Blood Corporation (the “Issuer”)

         
      (b) Address of Issuer’s Principal Executive Offices
         
     

    48th Floor, Bank of China Tower

    1 Garden Road

    Central, Hong Kong S.A.R.

         
    Item 2. (a) Name of Person Filing
         
     

    PAGAC III Holding VII Limited

    PAG Asia I LP

    PAG Asia Capital GP I Limited

    PAG Capital Limited

    Pacific Alliance Group Limited

    PAG (collectively, the “Reporting Persons”)

         
      (b) Address of Principal Business Office or, if none, Residence
         
     

    The registered address of PAGAC III Holding VII Limited is Commence Chambers, P.O. Box 2208, Road Town, Tortola, British Virgin Islands.

     

    The registered address of each of PAG Asia I LP, PAG Asia Capital GP I Limited, PAG Capital Limited, Pacific Alliance Group Limited and PAG is PO Box 472, 2nd Floor, Harbour Place, 103 South Church Street, George Town, Grand Cayman KY1-1106, Cayman Islands.

         
      (c) Citizenship
         
     

    The citizenship of each Reporting Person is as follows:

    PAGAC III Holding VII Limited – British Virgin Islands

    PAG Asia I LP – Cayman Islands

    PAG Asia Capital GP I Limited – Cayman Islands

    PAG Capital Limited – Cayman Islands

    Pacific Alliance Group Limited – Cayman Islands

    PAG – Cayman Islands

         
      (d) Title of Class of Securities
         
     

    Ordinary shares, par value US$0.0001 per share (“Ordinary Shares”)

         
      (e) CUSIP No.
         
      G39342103

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
           
     

    Not applicable.

     

       

     

     

    CUSIP No. G39342103 SCHEDULE 13G Page 9 of 11

     

     

    Item 4. Ownership
       
     

    The Ordinary Shares reported herein are held by PAGAC III Holding VII Limited. PAGAC III Holding VII Limited is wholly owned by PAG Asia I LP. The general partner of PAG Asia I LP is PAG Asia Capital GP I Limited. PAG Asia Capital GP I Limited is wholly owned by PAG Capital Limited. PAG Capital Limited is wholly owned by Pacific Alliance Group Limited. Pacific Alliance Group Limited is wholly owned by PAG.

     

    PAG Asia I LP, PAG Asia Capital GP I Limited, PAG Capital Limited, Pacific Alliance Group Limited and PAG, as a result, and by virtue of the relationships described above, may be deemed to beneficially own the shares owned by PAGAC III Holding VII Limited.

     

    Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.

     

    (a)Amount beneficially owned:
       
      See row 9 on the cover page of each Reporting Person.

     

    (b)Percent of class:
       
      See row 11 on the cover page of each Reporting Person.

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote:
       
      See row 5 on the cover page of each Reporting Person.

     

    (ii)Shared power to vote or to direct the vote:
       
      See row 6 on the cover page of each Reporting Person.

     

    (iii)Sole power to dispose or to direct the disposition of:
       
      See row 7 on the cover page of each Reporting Person.

     

    (iv)Shared power to dispose or to direct the disposition of:
       
      See row 8 on the cover page of each Reporting Person.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☐

       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person
       
      Not applicable.
       
    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
       
      Not applicable.
       
    Item 8. Identification and Classification of Members of the Group
       
      Not applicable.
       
    Item 9. Notice of Dissolution of Group
       
      Not applicable.
       
    Item 10. Certification
       
      Not applicable.

     

       

     

     

    CUSIP No. G39342103 SCHEDULE 13G Page 10 of 11

     

     

    Exhibit Index

     

    Exhibit No.

     

    Description

         
    99.1   Joint Filing Agreement, by and among the Reporting Persons, dated February 3, 2023

     

     

     

     

       

     

     

    CUSIP No. G39342103 SCHEDULE 13G Page 11 of 11

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 3, 2023

     

      PAGAC III HOLDING VII LIMITED  
             
      By: /s/ Jon Robert Lewis  
        Name: PAGAC Secretaries Limited, represented by Jon Robert Lewis  
        Title: Director  
             
      PAG ASIA I LP  
             
      By: /s/ Jon Robert Lewis  
        Name: PAG Asia Capital GP I Limited, represented by Jon Robert Lewis  
        Title: General partner of PAG Asia I LP  
             
      PAG ASIA CAPITAL GP I LIMITED  
             
      By: /s/ Jon Robert Lewis  
        Name: Jon Robert Lewis  
        Title: Director  

     

      PAG CAPITAL LIMITED  
             
      By: /s/ Jon Robert Lewis  
        Name: Pacific Alliance Group Limited, represented by Jon Robert Lewis  
        Title: Director  
             
      PACIFIC ALLIANCE GROUP LIMITED  
             
      By: /s/ Jon Robert Lewis  
        Name: Jon Robert Lewis  
        Title: Director  
             
      PAG  
             
      By: /s/ Derek Roy Crane  
        Name: Derek Roy Crane  
        Title: Director  

     

       
    Get the next $CO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CO
    SEC Filings

    View All

    SEC Form 6-K filed by Global Cord Blood Corporation

    6-K - Global Cord Blood Corp (0001467808) (Filer)

    2/12/24 5:06:46 PM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form 6-K filed by Global Cord Blood Corporation

    6-K - Global Cord Blood Corp (0001467808) (Filer)

    12/4/23 5:15:19 PM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form 6-K filed by Global Cord Blood Corporation

    6-K - Global Cord Blood Corp (0001467808) (Filer)

    9/29/23 4:33:27 PM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GLOBAL CORD BLOOD CORPORATION ANNOUNCES FAILURE TO FILE INTERIM FINANCIALS

    GEORGE TOWN, Cayman Islands and HONG KONG, April 13, 2023 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) (the "Company"), a provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services in China, announced that it received a notice (the "Notice") on April 3, 2023 from the New York Stock Exchange ("NYSE") with respect to its failure to timely file on Form 6-K its semi-annual financials for the six-month period ended September 30, 2022 (the "Interim Financials") as required by NYSE Listing Standard 203.03. As previously announced, on September 22, 2022, the Grand Court of the Cayman Islands issued an order (the "Order") appoi

    4/13/23 3:08:00 PM ET
    $CO
    Managed Health Care
    Health Care

    Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands

    Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that an order was made by the Grand Court of the Cayman Islands ("Grand Court") on September 22, 2022 (the "Order") appointing Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited and Chow Tsz Nga Georgia of Grant Thornton Recovery & Reorganisation Limited as the Joint Provisional Liquidators of the Company (the "Joint Provisional Liquidators"). Upon the making of the Order, the powers of the directors of the Company are suspended. Blue Oce

    9/26/22 4:07:00 PM ET
    $CO
    Managed Health Care
    Health Care

    The Grand Court of the Cayman Islands Granted Blue Ocean's Application to Appoint Joint Provisional Liquidators for Global Cord Blood Corporation

    Blue Ocean Structure Investment Company Ltd., ("Blue Ocean") a significant shareholder of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE:CO), today announced the Grand Court of the Cayman Islands (the "Court") issued an order granting the appointment of joint provisional liquidators ("JPLs") for Global Cord, pursuant to section 104(2) of the Companies Act (2022 Revision) (the "Companies Act"), upon the application filed by Blue Ocean dated 22 August 2022. Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited, 2nd Floor, Century Yard, Cricket Square, Grand Cayman KY1-1102, Cayman Islands and Chow Tsz Nga Georgia have been appointed as JP

    9/23/22 1:52:00 PM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Global Cord Blood Corporation (Amendment)

    SC 13G/A - Global Cord Blood Corp (0001467808) (Subject)

    2/14/24 10:15:21 AM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form SC 13G filed by Global Cord Blood Corporation

    SC 13G - Global Cord Blood Corp (0001467808) (Subject)

    2/14/23 10:23:43 AM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form SC 13G/A filed by Global Cord Blood Corporation (Amendment)

    SC 13G/A - Global Cord Blood Corp (0001467808) (Subject)

    2/3/23 2:38:38 PM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    Leadership Updates

    Live Leadership Updates

    View All

    Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands

    Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that an order was made by the Grand Court of the Cayman Islands ("Grand Court") on September 22, 2022 (the "Order") appointing Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited and Chow Tsz Nga Georgia of Grant Thornton Recovery & Reorganisation Limited as the Joint Provisional Liquidators of the Company (the "Joint Provisional Liquidators"). Upon the making of the Order, the powers of the directors of the Company are suspended. Blue Oce

    9/26/22 4:07:00 PM ET
    $CO
    Managed Health Care
    Health Care

    The Grand Court of the Cayman Islands Granted Blue Ocean's Application to Appoint Joint Provisional Liquidators for Global Cord Blood Corporation

    Blue Ocean Structure Investment Company Ltd., ("Blue Ocean") a significant shareholder of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE:CO), today announced the Grand Court of the Cayman Islands (the "Court") issued an order granting the appointment of joint provisional liquidators ("JPLs") for Global Cord, pursuant to section 104(2) of the Companies Act (2022 Revision) (the "Companies Act"), upon the application filed by Blue Ocean dated 22 August 2022. Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited, 2nd Floor, Century Yard, Cricket Square, Grand Cayman KY1-1102, Cayman Islands and Chow Tsz Nga Georgia have been appointed as JP

    9/23/22 1:52:00 PM ET
    $CO
    Managed Health Care
    Health Care

    Global Cord Blood Corporation Announces Results of 2021 Annual General Meeting

    HONG KONG, Dec. 7, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2021 Annual General Meeting of shareholders, held on December 7, 2021, in Hong Kong S.A.R., China. At the Annual General Meeting, the Company's shareholders ratified the re-appointment of KPMG Huazhen LLP as independent auditors of the Company for the financial year ending March 31, 2022, and authorized any duly formed committee of the directors to fix the remuneration of the independent auditors; and re-elected Ms.

    12/7/21 8:32:00 AM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    Financials

    Live finance-specific insights

    View All

    Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022

    Added 16,423 New Subscribers in 4QFY22 4QFY22 Revenues Down 1.7% YoY to RMB297.2 Million ($46.9 Million) 4QFY22 Gross Profit Down 0.5% YoY to RMB255.2 Million ($40.3 Million) 4QFY22 Operating Income Down 4.1% YoY to RMB142.1 Million ($22.4 Million) 4QFY22 Non-GAAP Operating Income Down 4.1% YoY to RMB153.9 Million ($24.3 Million) HONG KONG, July 5, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the fourth quarter and full year of fiscal 2022, ended March 31, 2022.

    7/5/22 4:16:00 PM ET
    $CO
    $INCY
    Managed Health Care
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2022

    Added 18,985 New Subscribers in 3Q22Revenues Up 9.1% YoY to RMB317.2 Million ($49.8 Million)         Gross Profit Up 9.8% YoY to RMB269.9 Million ($42.4 Million)Operating Income Up 20.8% YoY to RMB149.7 Million ($23.5 Million) Non-GAAP Operating Income Up 18.6% YoY to RMB161.6 Million ($25.4 Million)Conference Call to be Held on March 1, 2022, at 8:00 a.m. ET HONG KONG, Feb. 28, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the third quarter and first nine month

    2/28/22 4:16:00 PM ET
    $CO
    Managed Health Care
    Health Care

    Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2022 Financial Results

    HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release its financial results for the third quarter and first nine months of fiscal 2022 on Monday, February 28, 2022, after the U.S. market close.  The Company will host a conference call at 8:00 a.m. ET on Tuesday, March 1, 2022 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question-and-answer session. Interested parties can access the audio webcast through

    2/23/22 7:00:00 AM ET
    $CO
    Managed Health Care
    Health Care